A Phase IIIb, Open-label, Local, Multicenter Study of the Molecular Features of Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative Advanced Breast Cancer on First-line Treatment With Ribociclib and Letrozole

Trial Profile

A Phase IIIb, Open-label, Local, Multicenter Study of the Molecular Features of Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative Advanced Breast Cancer on First-line Treatment With Ribociclib and Letrozole

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Letrozole (Primary) ; Ribociclib (Primary)
  • Indications Breast cancer
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms BioItaLEE
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 27 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 30 Apr 2018.
    • 22 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top